Bicycle Therapeutics Ltd

Bicycle Therapeutics plc is a clinical-stage pharmaceutical company that develops medicines for diseases with limited treatment options in the United States and the United Kingdom. Its pipeline includes zelenectide pevedotin, a bicycle toxin conjugate (BTC) in phase II trials for high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC in phase I/II trials for Ephrin type A receptor 2 expressing tumors; BT7480, a Bicycle tumor-targeted immune cell agonist in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP with ongoing IND-enabling activities. The company also develops preclinical programs for novel CNS targets, novel neuromuscular targets, and radiopharmaceuticals. It collaborates with biopharmaceutical companies and organizations, including Bayer Consumer Care AG, Novartis Pharma AG, Ionis Pharmaceuticals, Inc., Genentech, Inc., and AstraZeneca AB. Incorporated in 2009, Bicycle Therapeutics plc is headquartered in Cambridge, the United Kingdom.